Clinical Trial

US Zamto-cel Autoimmune Diseases

Name: US Zamto-cel Autoimmune Diseases — clinical trial record (NCT06708845)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

Trial Details

NCT Number	NCT06708845
Lead Sponsor	Miltenyi Biomedicine GmbH
Conditions	Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Enrollment	48 participants
Start Date	2026-07
Primary Completion	2028-01 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-11